Spontaneous resolution of vitreomacular traction following ranibizumab (Lucentis) injection.
OBJECTIVE
Spontaneous resolution of vitreomacular traction syndrome in diabetic patients is a rare phenomenon that has been poorly described in the literature.


METHODS
Case presentation.


RESULTS
The authors present a case of spontaneous resolution of vitreomacular traction following intravitreal administration of ranibizumab.


CONCLUSIONS
In patients with vitreomacular traction syndrome and diabetic macular edema, the combination of the possible vitreous liquefaction and mechanical increase of vitreous volume caused by an intravitreal injection with a degree of reduction in retinal thickness caused by the effect of vascular endothelial growth factor inhibition could play a role in the resolution of vitreomacular traction.
Rouvas
A
A
Second Ophthalmology Department, University of Athens, Attikon Hospital, Athens, Greece.
Petrou
P
P
Ladas
I
I
Neamonitou
G
G
Vergados
I
I
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D003930:Diabetic Retinopathy / Q000150:complications; D005128:Eye Diseases / Q000175:diagnosis / Q000188:drug therapy*; D005451:Fluorescein Angiography; D006801:Humans; D007267:Injections; D008269:Macular Edema / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D008297:Male; D000069579:Ranibizumab; D012075:Remission, Spontaneous; D012164:Retinal Diseases / Q000175:diagnosis / Q000188:drug therapy*; D013577:Syndrome; D000267:Tissue Adhesions / Q000175:diagnosis / Q000188:drug therapy; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014822:Vitreous Body / Q000187:drug effects* / Q000473:pathology
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000069579:Ranibizumab